Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
CNS Therapeutics logo — Delivering advanced neurological and pain treatments with pr...

CNS Therapeutics

Delivering advanced neurological and pain treatments with precision and expertise

Founded 2007 United States Saint Paul, United States 4 employees Venture round Total: $10.05M Biotechnology, Health Care

General Information

Company Name CNS Therapeutics
Founded Year 2007
Location United States Saint Paul, United States
Employees 4
Industries Biotechnology, Health Care
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with CNS Therapeutics. To contact CNS Therapeutics, visit cnstherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does CNS Therapeutics compare?

A PDF of CNS Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting CNS Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About CNS Therapeutics

CNS Therapeutics is a biotechnology and healthcare startup based in St. Paul, Minn., dedicated to delivering advanced neurological and pain treatments with precision and expertise. Established in 2007, the company has positioned itself as a leader in the development and marketing of high-quality pharmaceuticals tailored for targeted delivery to the central nervous system, focusing on addressing neurological disorders and chronic pain. The firm's first FDA-approved product, Gablofen, marks a significant milestone in its journey. It is currently engaged in active partnerships with U.S. and international scientific experts to develop and assess new treatments for pain and Parkinson's disease. In December 2012, CNS Therapeutics secured a substantial $3.05M Venture Round investment, indicative of investor confidence in the company's potential and its innovative approach to tackling neurological and pain-related conditions. This injection of funds demonstrates a recognition of CNS Therapeutics' capabilities and the promise it holds for addressing unmet medical needs. As the company continues to expand its reach and bolster its product pipeline, it stands poised to make a meaningful impact in the biotechnology and healthcare sectors with its specialized focus on neurological and pain treatments.

Business keywords: neurological disorders, chronic pain, pharmaceuticals, central nervous system, precision medicine, FDA-approved, Gablofen, drug development, scientific collaboration, Parkinson's disease, site-specific delivery, biopharmaceuticals, expertise, clinical trials

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $3.05M -
21 Dec 2012
Venture Round $7.00M -
18 Aug 2009

CNS Therapeutics Alternatives & Competitors

View All Alternatives
CNS Therapeutics vs
Hoba Therapeutics
Hoba Therapeutics Denmark

Developing Restorative Treatments for Chronic Neuropathic Pain and Hearing Loss

Series A
15 employees
Biotechnology, Health Care
CNS Therapeutics vs
Alcyone Lifesciences
Alcyone Lifesciences

Empowering Precision Therapies for Rare Neurological Disorders

Venture round
Biotechnology, Health Care
CNS Therapeutics vs
Ophidion
Ophidion

Advancing brain-targeted therapies with precision and innovation for neurodegenerative and anxiety-r...

Convertible Note
Biotechnology, Health Care
View all alternatives

FAQ About CNS Therapeutics

Delivering advanced neurological and pain treatments with precision and expertise
CNS Therapeutics was founded in 2007.
CNS Therapeutics is headquartered in Saint Paul, United States.
CNS Therapeutics operates in Biotechnology and Health Care. Its work centres on neurological disorders, chronic pain, pharmaceuticals and central nervous system.
CNS Therapeutics has approximately 4 employees.
CNS Therapeutics has completed 2 funding rounds, raising a total of $10.05M. The latest funding stage is Venture round.
Top alternatives and competitors to CNS Therapeutics include Hoba Therapeutics, Alcyone Lifesciences, Ophidion, Cerebral Therapeutics, Inc., Neurolixis. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CNS Therapeutics and Hoba Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for CNS Therapeutics, https://bouncewatch.com/company/cns-therapeutics, updated 11 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout